Publications by authors named "Nan Mou"

Claim this Profile
E
Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma.
Yi Li Jiang, Juan Mu, Rui Cui, Xin Li, Jia Wang, Nan Mou

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Xiupeng Ye, Xuemei Fan, Rui Cui, Juan Mu, Meijing Liu, Nan Mou

Ann Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.
Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Nan Mou

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy.
Pu Yao, Xiaowen Wang, Qianmei Wang, Qing Dai, Yu Peng, Nan Mou

Pharmaceutics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Qing Li, Cuicui Lyu, Meijing Liu, Jia Wang, Nan Mou

Cell Transplant· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity.
Lin Cheng, Bangbi Weng, Changsheng Jia, Lin Zhang, Bin Hu, Nan Mou

Front Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luteolin attenuates the pathogenesis of Staphylococcus aureus by interfering with the agr system.
Qian Yuan, Wei Feng, Yu Wang, Qianmei Wang, Nan Mou

Microb Pathog· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy.
Xin Li, Mei-Jing Liu, Nan Mou, Zhen-Xing Yang, Jia Wang

Oncol Lett· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.
Cuicui Lyu, Rui Cui, Jia Wang, Nan Mou, Yanyu Jiang

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
Rui Cui, Cuicui Lyu, Qing Li, Yanyu Jiang, Nan Mou

Hematol Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
Jia Wang, Nan Mou, Zhenxing Yang, Qing Li, Yanyu Jiang

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant.
Pengjiang Liu, Meijing Liu, Cuicui Lyu, Wenyi Lu, Rui Cui, Nan Mou

Front Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis